Analyzing Insulet (NASDAQ:PODD) and NWT Uranium (OTCMKTS:CPTRF)

NWT Uranium (OTCMKTS:CPTRF) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NWT Uranium and Insulet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NWT Uranium	0	0	0	0	0.00
Insulet	1	5	18	0	2.71

Insulet has a consensus target price of $327.24, indicating a potential upside of 72.63%. Given Insulet’s stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than NWT Uranium.

Valuation & Earnings

This table compares NWT Uranium and Insulet”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NWT Uranium	$27.25 million	N/A	$6.69 million	$4.08	0.04
Insulet	$2.71 billion	4.85	$247.10 million	$3.50	54.16

Insulet has higher revenue and earnings than NWT Uranium. NWT Uranium is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NWT Uranium and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NWT Uranium	N/A	-157.37%	-147.81%
Insulet	9.12%	24.90%	10.73%

Summary

Insulet beats NWT Uranium on 9 of the 10 factors compared between the two stocks.

About NWT Uranium

Captor Capital Corp. engages in the manufacture and retail sale of cannabis products in the United States. It operates two dispensaries under the CHAI Cannabis Co. brand in Santa Cruz and Monterey, California, as well as operates an e-commerce site under the CHAI-brand. The company was formerly known as NWT Uranium Corp. and changed its name to Captor Capital Corp. in June 2017. Captor Capital Corp. was incorporated in 2003 and is based in Toronto, Canada.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.